Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for their disease go from zero to three. | The FDA on Wednesday gave the thumbs ...

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.

Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...

Roche’s shares have risen 10.6% year to date against the industry’s decline of 1.2%. Image Source: Zacks Investment Research Strong demand for key drugs and diagnostic solutions offset the ...